Cytochrome a3 Inhibitors
4 drugsAbout Cytochrome a3
Cytochrome a3 is a critical component of the mitochondrial electron transport chain, essential for cellular respiration. It facilitates the final transfer of electrons to oxygen, generating water and contributing to the proton gradient that drives ATP synthesis.
While not directly linked to common diseases genetically, Cytochrome a3 is targeted by four FDA-approved drugs. These drugs are used in specific toxicological scenarios, modulating its activity in acute poisoning or toxicity events.
Four approved small molecule drugs, including CYANOKIT, NITHIODOTE, SODIUM NITRITE, and SODIUM THIOSULFATE, target Cytochrome a3. These drugs are marketed by HOPE PHARMS and BTG INTL for 'other' therapeutic areas related to toxicity.
Top Cytochrome a3 Drugs
The competitive landscape is concentrated, with HOPE PHARMS and BTG INTL holding all approved drugs.
High market concentration suggests potential entry barriers for new companies.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| NITHIODOTE | HOPE PHARMS | 2011 | 1 |
Cytochrome a3 Drug Modality Landscape
Modalities
Routes of Administration
Cytochrome a3 is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies could create differentiation in this space.
Cytochrome a3 Clinical Trials 73 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Cytochrome a3. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 19 | 12 | 5 | 2 | 71% |
| Phase 2 | 41 | 27 | 11 | 3 | 71% |
| Phase 3 | 8 | 1 | 3 | 4 | 25% |
| Phase 4 | 5 | 4 | 1 | 0 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Cytochrome a3 Drug Approval Timeline (1992 - 2012)
Drug approvals for Cytochrome a3 span 21 years, from 1992 to 2012.
The relatively long period since the last approval suggests a potentially saturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 52 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Cytochrome a3. A trial counts if an approved drug acting on Cytochrome a3 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.